We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Finds Keytruda Not Cost-Effective in Bladder Cancer
NICE Finds Keytruda Not Cost-Effective in Bladder Cancer
The UK National Institute for Health and Care Excellence ruled that Merck’s cancer immunotherapy Keytruda is not cost-effective in metastatic urothelial carcinoma.
